Scientists at Hansoh Bio LLC, Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have divulged transcriptional coactivator YAP1 or TAZ/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer.
Scientists at Shanghai Haiyan Pharmaceutical Technology Co. Ltd. and Yangtze River Pharmaceutical Group have identified high affinity nerve growth factor receptor (NTRK1; TrkA) inhibitors reported to be useful for the treatment of pain, cancer, inflammation and neurodegenerative diseases.
Baylor College of Medicine has disclosed proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to Bruton tyrosine kinase (BTK)-, DNA-binding protein Ikaros (IKZF1)- and Zinc finger protein Aiolos (IKZF3)-targeting moieties through a linker.
Elevation Oncology Inc. has nominated EO-1022 as its HER3 antibody-drug conjugate (ADC) development candidate for the treatment of solid tumors that express HER3.
Opna Bio AG has presented promising data regarding their EP300/CBP inhibitor OPN-6602 for the treatment of multiple myeloma (MM). The inhibition of EP300/CBP causes cell cycle arrest and apoptosis in MM cells due to suppression of interferon regulatory factor 4 (IRF4) and MYC repression.
Peptidream Inc. has announced a new peptide radiopharmaceutical development candidate, PD-29875, a novel first-in-class highly selective macrocyclic peptide-radioisotope conjugate against Claudin 18.2 (CLDN18.2).
To address the existing challenges with CAR T-cell therapy, scientists at Umoja Biopharma Inc. developed the Vivovec platform, which is an off-the-shelf surface-engineered lentiviral vector (LVV) drug product designed to generate CAR T cells in vivo without lymphodepletion by selectively binding, activating and transducing T cells.
Scientists at Institute of Materia Medica Chinese Academy of Medical Sciences & Peking Union Medical College have identified compounds reported to be useful for the treatment of cancer.
Previous research suggested that gram-negative bacteria may hold potential for cancer immunotherapy because they contain agonists for multiple immune receptors.
RSS
